ArticleThe pharmacogenomics journal2014
Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study.
Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions.Frontiers in pharmacology · 2022Article
- Genetic Determinants inJournal of personalized medicine · 2021Review
- Drug hypersensitivity reactions in Asia: regional issues and challenges.Asia Pacific allergy · 2020Review
- Multidisciplinary care in Stevens-Johnson syndrome.Therapeutic advances in chronic disease · 2020Review
- Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation ofFrontiers in pharmacology · 2020Article
- Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?Pharmaceutical medicine · 2019Article
- Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore.Pharmacology research & perspectives · 2019Article
- Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.Annual review of pharmacology and toxicology · 2019Review
- Pharmacogenetic testing in oncology: a Brazilian perspective.Clinics (Sao Paulo, Brazil) · 2018Review
- Applications of pharmacogenomics in regulatory science: a product life cycle review.The pharmacogenomics journal · 2018Review
- Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study.British journal of clinical pharmacology · 2016Observational
- Increased risk of strontium ranelate-related SJS/TEN is associated with HLA.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Article
- Pharmacogenomics in the clinic.Nature · 2015Review
- Global implementation of genomic medicine: We are not alone.Science translational medicine · 2015Review
- PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Pharmacogenetics and genomics · 2015Article
- SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.The journal of allergy and clinical immunology. In practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the possible genetic associations with adverse drug reactions (ADR), the Singapore Health Sciences Authority (HSA) has piloted a program to collect DNA and phenotype data of ADR cases as part of its pharmacovigilance program. Between 2009 and 2012, HSA screened 158 cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). To assess the association between HLA-B*1502 and carbamazepine (CBZ)-induced SJS/TEN, 13 cases and 26 drug-tolerant controls were analyzed. All 13 CBZ-SJS/TEN cases and 3/26 controls were HLA-B*1502 positive (odds ratio 181, 95% confidence interval: 8.7-3785, P=6.9 × 10(-8)). Discussions of the finding with the Ministry of Health and an expert panel led to the decision to make HLA-B*1502 testing the standard of care prior to first use of CBZ in Asians and to subsidize the genotyping test at public hospitals. This program illustrates the role of a regulatory authority in advancing the use of pharmacogenetics for drug safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.